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2 Background: Current guidelines recommend viral, autoimmune, coagulation and liver 
3 ultrasound testing in intrahepatic cholestasis of pregnancy (ICP) to exclude alternative 
4 diagnoses. 
5
6 Methods: Electronic health records were searched for investigations and diagnoses in 
7 women with raised bile acid (BA) concentrations (>10 µmol/L) between January 2016-
8 December 2017 at two UK maternity units.
9
10 Results: 531 women had a raised BA concentration (median (IQR): 18 (13-32 µmol/L)) at a 
11 median gestation of 35.1 (IQR 31.8-37.0) weeks. 250/531 (47.1%) had full virology, 
12 autoimmune and ultrasound tests. 348/531 (65.5%) had coagulation performed. Positive 
13 hepatitis B and C results were previously known. No new Epstein-Barr Virus, 
14 Cytomegalovirus or hepatitis A diagnoses were made. There were 11 positive autoimmune 
15 results, but no new diagnoses. No women had unexplained prolonged prothrombin time. No 
16 ultrasound liver (n=38) or gallbladder (n=85) abnormalities were of acute clinical 
17 significance. 
18
19 Conclusion:  ICP investigations provided no new diagnoses that influenced clinical 
20 management during pregnancy. 































































23 Intrahepatic cholestasis of pregnancy (ICP) or obstetric cholestasis is the commonest 
24 pregnancy-specific liver disease, affecting approximately 0.7% of pregnancies in multi-ethnic 
25 populations in the UK.1 It has a multifactorial aetiology with genetic, hormonal and 
26 environmental components,2–4 with higher incidence noted in women of Asian-Pakistani 
27 (1.5%) and Asian-Indian (1.2%) origin.5 ICP is diagnosed by the combination of pruritus and 
28 elevated bile acids (BA) in pregnancy, in the absence of another identified cause, with 
29 resolution of clinical symptoms and biochemical abnormalities expected within weeks of 
30 delivery. 
31
32 Current guidelines advocate approaching ICP as a diagnosis of exclusion. The Royal College 
33 of Obstetricians & Gynaecologists (RCOG) Obstetric Cholestasis Green-top Guideline (last 
34 updated in 2011) recommends that ‘other causes of pruritus and abnormal liver function 
35 tests should be sought’, suggesting viral testing for Hepatitis A, B, C, Epstein Barr Virus and 
36 cytomegalovirus, liver autoimmune testing for chronic active hepatitis and primary biliary 
37 cirrhosis, liver ultrasound and that ‘a coagulation screen should be performed’.6 The 
38 principal aim of this testing in the antenatal period is to identify alternative causes for the 
39 clinical presentation (i.e. pruritus and raised bile acid concentrations). However, the 
40 proportion of women with suspected ICP who have additional investigations and the 
41 detection rate for alternative diagnoses or co-morbidities as a result of testing in ICP is 
42 uncertain.































































44 All tests for bile acid concentrations performed in two London hospital maternity units 
45 between 1 January 2016 – 31 December 2017 were reviewed. Women with a peak bile acid 
46 concentration above the upper limit of normal (>10 µmol/L in both units) were identified. 
47 Data review was performed to remove records of non-pregnant women and those in whom 
48 bile acid concentration was measured following stillbirth without any clinical symptoms or 
49 preceding diagnosis of ICP. Following data cleaning, hospital laboratory databases were 
50 reviewed to determine which investigations were performed during pregnancy and the 
51 results of these investigations (biochemistry, virology, autoimmune antibodies, coagulation 
52 and liver ultrasound) and clinical outcomes were extracted from electronic health record 
53 databases. In women with abnormal investigation results and those with severe early-onset 
54 disease (defined as a peak bile acid level of ≥40 µmol/L at <32 weeks’ gestation), all 
55 available electronic health records including discharge summaries and clinic letters were 
56 reviewed in order to determine whether any new diagnoses were made. Data manipulation 
57 and analysis was performed in R version 3.4.3 (The R project for Statistical Computing). 
58 ANOVA and Kruskal-Wallis tests for continuous and Chi-Squared trend test for categorical 
59 variables were used to assess for differences between peak bile acid concentration groups 
60 as appropriate. 
61































































The selection of women with a peak bile acid concentration of >10 µmol/L during pregnancy 
during the 2-year study period is shown in Figure 1. Out of 23,927 deliveries at both hospital 
sites, 531 (2.2%) women had raised bile acid concentrations with first raised bile acid at a 
median gestation age of 35.1 weeks (interquartile range (IQR) 31.8-37.0). 184 women 
(34.7%) had a peak bile acid concentration ≥40 µmol/L during their pregnancy (at a median 
gestational age of 34.3 (IQR 32.1-36.5) weeks). 
Maternal demographics
Maternal demographics in women with raised bile acids during pregnancy are shown in 
Table 1. There were 47 (8.9%) twin pregnancies.
Delivery and fetal outcomes 
Delivery and fetal outcomes in women are shown in Table 2. Women with a peak bile acid 
concentration of ≥40 µmol/L delivered at earlier gestations. There were high rates of 
induction of labour (between 38.9% and 54.6%) in all groups, with approximately 50% of 
women overall being induced and 19% having planned delivery by caesarean section. 
Overall 19% of women delivered preterm (prior to 37 weeks’ gestation), of whom 25.7% 
went into spontaneous preterm labour. 4% of women delivered very preterm (at <34 weeks’ 
gestation), of whom 33.3% had spontaneous onset of preterm labour. There were two 
stillbirths (0.3% of births) at 31 and 35 weeks’ gestation, both of which occurred in women 
who had a peak bile acid concentration of ≥100 µmol/L during pregnancy, and with 
additional maternal comorbidities alongside ICP. There was one neonatal death (0.2% of 
births) of one baby of twins delivered at 32 weeks’ gestation by elective Caesarean section 
for suspected twin to twin transfusion in whom the woman had a peak bile acid 
concentration of 42 µmol/L. 
Biochemistry testing
Other biochemistry results at time of first raised bile acid are summarised in Table 3. 
Women who had a peak bile acid concentration ≥40 µmol/L during pregnancy presented 
with higher initial raised bile acids, and with higher associated concentrations of alanine 
transaminase. There were 15 women (2.8%) who had raised bilirubin at time of peak bile 






























































acid, of which 7 (1.3%) cases were elevated sufficiently (>34-42 umol/L) to cause clinical 
jaundice.
Virology testing 
A summary of virology, autoimmune and ultrasound testing and results is shown in Table 4. 
380 (71.6%) women were tested for Epstein Barr Virus (EBV): of these, 343 (90.3%) women 
were immune (EBV Viral Capsid Antigen (VCA) IgG positive, IgM negative), 13 (3.4%) were 
susceptible (EBV VCA IgG and IgM negative), and 24 women (6.3%) were both EBV VCA IgG 
and IgM positive which can denote recent infection. In these latter cases, further testing for 
Epstein-Barr nuclear antigen (EBNA) was performed. Twenty three women tested positive 
for EBNA denoting past (minimum of 6-8 weeks previously) rather than acute infection, and 
one woman tested EBNA negative; however she had a low positive EBV VCA IgM result 
which was reported by the virology team as ‘consistent but not typical of primary EBV 
infection’, no testing for EBV viral load was performed and no clinical diagnosis was made 
on review of electronic health records. 
Of the 395 (74.4%) women tested for cytomegalovirus (CMV), 170 (43.0%) were immune 
(CMV IgG positive, CMV IgM negative/not tested in two cases), 181 (45.8%) tested negative 
for CMV IgM (IgG testing was not performed), 37 (9.4%) were susceptible to CMV infection 
(CMV IgG and IgM negative), and seven women (1.7%) tested positive for CMV IgG and IgM 
which can denote recent infection. In these seven women, three were tested for CMV DNA 
and were all negative, two had repeat CMV serology with no interval change (thus excluding 
acute infection) and in two cases booking serology was tested and CMV IgG was positive 
suggesting the women were immune and the CMV IgM was a false positive in pregnancy.
Seven (1.4%) of the 496 (93.4%) women tested for Hepatitis B infection had Hepatitis B 
surface antigen detected of whom six had known diagnoses, including two in whom the 
diagnosis had been made at booking in the same pregnancy. The status of one woman who 
tested positive for Hepatitis B infection could not be ascertained as she had a single 
attendance at one hospital site whilst visiting London and had booked her pregnancy 
elsewhere.






























































Of the 421 (79.3%) women tested for Hepatitis C infection, three (0.7%) were positive, in all 
of whom the diagnosis had been made prior to the pregnancy. Of the 387 (72.9%) women 
tested for Hepatitis A infection, there were no positive IgM results. 
Autoimmune testing 
Autoantibody testing for smooth muscle antibodies
404 (76.1%) women were tested for smooth muscle antibodies of whom five (1.2%) were 
positive. None of the women with positive smooth muscle antibodies tested positive for any 
of the viral infections, anti-mitochondrial antibodies, or liver/kidney microsomal antibodies. 
ICP only was the recorded diagnosis in all cases on review of the electronic health records 
and clinic letters and none were referred to gastroenterology or hepatology services. 
Further details are given in Supplementary Text 1. 
Autoantibody testing for antinuclear antibodies
Hep-2 antinuclear antibody (ANA) testing was performed as part of the ICP investigations at 
one hospital site only. Of the 227 women tested for Hep-2 ANA, 31 (13.7%) had antibodies 
detected, with only two at dilutions of 1:640 or 1:1280. Most women had known pre-
existing diagnoses, including autoimmune diseases. On review of electronic health records 
and clinic letters, no new diagnoses other than ICP were made as a result of testing. Further 
details are given in Supplementary Text 2.
Autoantibody testing for anti-mitochondrial antibodies and liver kidney microsomal 
antibodies
403 (75.9%) women were tested for anti-mitochondrial antibodies, of whom five (1.2%) 
were positive. Three women were referred to gastroenterology/hepatology services and 
discharged after further investigations. In the remaining cases no referrals to specialist 
services were made and no new clinical diagnoses other than ICP were evident on electronic 
health records and clinic letters. Further details are given in Supplementary Text 3. Of the 
406 women tested for liver kidney microsomal antibody there were no positive results. 
Ultrasound testing for comorbidities and additional diagnoses






























































In total 327 (61.6%) women had a liver and gallbladder ultrasound as part of ICP 
investigations. There were high rates of co-incidental findings on imaging, shown in 
supplementary Table 1. Eighty-five women (26.2%) had gallbladder abnormalities detected 
including 60 women (18.5%) with gallstones and/or biliary sludge, 12 (3.7%) with a polyp, 10 
(3.1%) with previous cholecystectomy, and three other minor abnormalities (debris noted in 
gallbladder, gallbladder wall thickened, mild gallbladder oedema).
Coagulation testing
348 women (65.5%) had coagulation tests performed. Three had a prolongation of 
prothrombin time; one also had severe pre-eclampsia and HELLP [haemolysis, elevated liver 
enzymes, low platelets] syndrome necessitating delivery at 30 weeks’ gestation, and two 
had acute fatty liver of pregnancy.
Diagnoses in women presenting with early onset rise in bile acid concentrations
There were 23 women (4.3%) who had a peak bile acid concentration of ≥40 µmol/L at less 
than 32 weeks’ gestation, ten (43.5%) of whom had a peak bile acid concentration of ≥100 
µmol/L during pregnancy. In 12/23 cases (52.2%) ICP was the only liver diagnosis during 
pregnancy with no additional comorbidities of note. In the remaining cases pre-existing 
comorbidities, alternative explanations for the abnormal liver function tests and/ or 
additional pregnancy complications were present. Full details are in Supplementary Text 4 
and Supplementary Table 2.
Characteristics of testing
In total 250/531 (47.1%) of women with raised bile acids during pregnancy had complete 
virology, autoimmune and ultrasound tests. Only 24 (4.5%) women had no additional tests. 
There were no significant differences in the proportion of women with peak bile acid 
concentration of 11-39 µmol/L, 40-99 µmol/L or ≥100 µmol/L or more that had full virology 
testing (p=0.244, 62.8%, 70.0%, 70.4% tested, respectively), or autoimmune testing 
(p=0.514, 74.4%, 78.5%, 79.6% tested respectively). However women with higher peak bile 
acids were more likely to have a liver ultrasound (p=0.015, 57.3%, 66.2%, 75.9%  
respectively). 






























































Cost of additional investigations in ICP
The cost for a full set of ICP blood investigations (virology and autoimmune) for a single 
woman, estimated utilising Viapath Laboratory Services costs, was £130.67; the cost of an 
abdominal ultrasound within the NHS is estimated to be £150; coagulation screen costs 
£3.50. Therefore, we estimate around £35,000 per year was spent investigating women 
across the two hospitals. If all women had received all tests as recommended by the RCOG 
Green-top guidelines this would equate to £75,000 per year across the two sites. 
Discussion
Principal findings
In our study cohort of pregnant women with raised serum bile acid concentrations of >10 
µmol/L, there were no new diagnoses that resulted in ongoing specialist management 
detected from additional investigations routinely performed in clinical practice. 
Approximately one in five women who had bile acids tested in pregnancy had elevated 
serum bile acid concentrations of >10 µmol/L. Of the women with raised bile acid 
concentrations, approximately half of women had a full set of virology, autoimmune and 
ultrasound testing investigations, as currently recommended by national guidelines. Our 
data show that amongst women tested, over 95% were already immune to EBV. The cost of 
performing additional routine testing for ICP is substantial, for minimal, if any, new clinical 
information. There were no antenatal characteristics relating to the women, or the initial 
bile acid concentration, that identified a sub-group of women who might benefit from 
additional testing.  
Strengths and weaknesses
The strength of our study is that it is a two-centre study in a large city with a multi-ethnic 
population addressing a real-world, clinical conundrum. However, as we selected women 
with raised bile acids in pregnancy rather than a clinically defined population of women with 
suspected ICP it is possible that our study included women with alternative diagnoses, 
increasing our denominator and so diluting our reported rates of investigation. Bile acids 
can be raised in several hepatobiliary conditions including hepatitis, obstructive jaundice 
and cirrhosis7 as well as in pre-eclampsia, but bile acids are not usually tested in these 
conditions during or outside of pregnancy. In addition, the electronic health record review 






























































was limited to the hospital at which the initial bile acid test was performed and where the 
care during pregnancy and the postpartum period was provided, so it is possible that some 
women with hepatic diseases, e.g. autoimmune hepatitis, were not ascertained, if electronic 
records did not adequately capture other specialty involvement subsequent to the 
pregnancy. However, as pregnancy outcome data were available for all but 25 (4.3%) 
women, it appears that the majority of women received antenatal care and delivered within 
the two hospital Trusts.  
Comparison with other studies
In a UK series  of 70 patients with ICP, ultrasound scans revealed gallstones in 10% of 
women, and two (2.9%) cases of Hepatitis C were detected as a result of virology testing.8 In 
a French series reporting clinical characteristics of 50 women with ICP, virology testing did 
not reveal any concomitant liver disease and ultrasound examination was normal in all 
women.9 In a published Scandinavian cohort of 91 women negative virology testing and 
normal liver ultrasound defined the ICP cohort and the number of women excluded on the 
basis of positive virology results were not reported.10  One case in our study had genetic 
variation in ABCB4 and ABCB11, consistent with the findings of a UK study in which 
pathogenic mutations in these biliary transporters were identified in approximately 20% 
cases.11 None of these studies specifically investigated the clinical utility of additional 
investigations in ICP. Recommendations in the RCOG guidelines for management of ICP 
were based on expert opinion alone. 
Implications for clinicians and policymakers
Our findings suggest that the currently recommended routine additional investigations have 
no diagnostic yield and that a more targeted testing approach should be advocated. This is 
especially pertinent in an era in which healthcare efficiency is  increasingly relevant, and the 
Academy of Medical Royal Colleges is encouraging avoidance of unnecessary testing and 
procedures through the Choosing Wisely programme (see: 
http://www.choosingwisely.co.uk/about-choosing-wisely-uk/). This extends to autoantibody 
testing, where a focus on not testing persons with  a low pre-test probability of disease has 
been proposed.12 Reducing unselected testing would save money and allow resources to be 






























































focussed on women with atypical disease, clinical uncertainty, women with additional 
comorbidities or if postpartum resolution does not occur. 
Conclusion
Our data suggest little diagnostic value of routine additional testing investigations in ICP in 
women presenting with typical features. A more targeted and individualised approach could 
be used, based on factors such as atypical clinical symptoms, presence of comorbidities, 
severity of ICP, gestational age at presentation or failure of liver function tests to normalise 
postpartum. 
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Figure 1. Flow diagram illustrating selection of women with raised bile acid concentrations in 
pregnancy. BA: bile acid.






























































Table 1. Maternal demographics of women with bile acid concentration > 10 µmol/L during 






















































BMI (kg/m2) (median [IQR]) 23.6 [20.8-27.2] 25.0 [23.0-28.0] 24.0 [21.9-27.7]












































































































Table 2. Delivery and perinatal outcomes in women with raised bile acid concentration in all women 
and grouped by peak bile acid concentration. Results displayed as median [interquartile range] or 
number (%). 
Peak bile acid concentration (µmol/L)
Delivery outcomes All women






n = 54 
p-value*






































- Induction of labour




- Induction of labour





































































n = 578 n = 376 n = 145 n = 57 



























































































































































*p-values denoting results of tests for difference between peak bile acid concentration groups (11-
39, 40-99 and ≥100µmol/L). 






























































Table 3. First raised bile acid concentration (> 10 µmol/L), liver function test results and gestational 
age at time of first raised bile acid result in all women and grouped by subsequent peak bile acid 
concentration. 
*Comparing biochemistry results between peak bile acid concentration groups 11-39, 40-99 and 
100+ µmol/L.
Peak bile acid concentration (µmol/L)












First bile acid > 10 
µmol/L 
18 [13-32] 15 [12-20] 41 [25-55] 59 [25-127] <0.001
Gestation (weeks) 35.1 [31.8-37.0] 35.7 [31.4-37.3] 34.6 [32.4-36.6] 33.4 [30.3-36.3] 0.188
Bilirubin (µmol/L) 7 [5-10] 6 [4-9] 7 [5-11] 9 [6-15] <0.001
Alanine transaminase 
(IU/L)
40 [20-106] 31 [17-76] 72 [36-145] 78 [40-189] <0.001
Gamma-glutamyl 
transferase IU/L)
21 [14-35] 20 [12-31] 25 [16-44] 26 [14-38] 0.021






























































Table 4. Summary of screening investigations  (virology, autoimmune and ultrasound) in women with raised 
















Virology 11-39 40-99 100+
EBV serology






0/1 (0.0) 0/188 (0.0)
CMV serology
All women (n=531) 395 (74.4) 0/395 (0.0) - - - - -
Hepatitis C IgG






3/3 (100) 0/421 (0.0)
Hepatitis B sAg 










All women (n=531) 387 (72.9) 0/387 (0.0) - - - - -
Autoimmune 
Smooth muscle Ab
















1/1† (100) 0/227 (0.0)
Mitochondrial Ab






1/5‡ (25.0) 0/405 (0.0)
Liver/kidney 
microsomal Ab
All women (n=531) 406 (76.5) 0/406 (0.0)
- - - - -
Imaging
Liver ultrasound

















*Not booked at GSTT, single attendance. EBV: Epstein Barr Virus. CMV: Cytomegalovirus. sAg: surface 
antigen. Ab: antibody. 
†Known Ro and anti-PL-12 positive anti-synthetase syndrome positive interstitial lung disease prior to 
pregnancy. 
‡Known rheumatoid arthritis prior to pregnancy.













































































Heterogenous echotexture§ 2 (0.6)
Total 38 (11.6)
*1 – debris noted in gallbladder, 2 - gallbladder wall thickened, 3 – mild gallbladder oedema.
†In one case haemangioma was picked up in a woman with known Hepatitis C.
‡1 - Small calcific focus, 2 - prior surgical resection, 3 - known focal nodular hyperplasia who 
had further ultrasound in pregnancy to determine if there was any enlargement. 
§In one case heterogenous echotexture was noted in a woman known Hepatitis B who had 
regular liver ultrasound scans.






























































Supplementary Table 2. Rates of positive test results comparing between women with 
severe early-onset disease and those without. 
Severe early-onset disease 
(peak BA ≥40 µmol/L at 
<32/40 weeks gestation)
n=23
Non severe early-onset 
disease
n=508
Hep C IgG 1/21 (4.8) 2/400 (0.5)
Hep B sAg 0/22 (0.0) 7/474 (1.5)
Hep A IgM 0/22 (0.0) 0/368 (0.0)
Smooth Muscle Ab 1/17 (5.9) 4/387 (1.0)
Mitochondrial Ab 1/17 (5.9) 4/386 (1.0)
Liver/kidney microsomal Ab 0/23 (0.0) 0/387 (0.0)
Liver pathology 2/20 (10.0) 36/306 (11.8)
Gallbladder pathology 7/20 (35.0) 78/303 (25.7)
































































Autoantibody testing for smooth muscle antibodies
404 (76.1%) women were tested for smooth muscle antibodies of whom five (1.2%) were 
positive: three at 1:80 dilution and two at 1:40. One woman also had Hep-2 ANA antibodies 
detected at 1:80 dilution. Median liver function test results in these women at time of first 
raised bile acid were: bilirubin 7 (IQR 4-7) µmol/L, alanine transaminase 104 (IQR 21-186) 
IU/L, and gamma-glutamyl transferase 31 (15-38) IU/L. Liver function tests (other than bile 
acid concentrations) were normal during pregnancy in one woman, resolved postpartum in 
two women, were not checked post-delivery in one woman and remained elevated (62IU/L) 
at 2 months postpartum in one woman. 
Supplementary Text 2
Autoantibody testing for antinuclear antibodies
Hep-2 antinuclear antibody (ANA) testing was performed as part of the ICP investigations at 
one hospital site only. Of the 227 women tested for Hep-2 ANA, 31 (13.7%) had antibodies 
detected; 14 at 1:40 dilution, 12 at 1:80 dilution, 3 at 1:160 dilution, 1 at 1:640 dilution and 
1 at 1:1280 dilution. Several women had pre-existing autoimmune disease diagnoses 
including the woman with an ANA titre of 1:1280 who had a diagnosis of fibrotic interstitial 
lung disease, anti-synthetase syndrome and was also known to be anti-Ro and anti-PL-12 
antibody positive. She was not referred for hepatology specialist review as her liver function 
tests remained in the normal range throughout pregnancy and her raised antibodies were 
considered to be related to her autoimmune lung disease. Other pre-existing diagnoses in 
this group of women were sickle cell disease with antiphospholipid syndrome (1:80 
dilution), Grave’s disease (1:80 dilution) and ulcerative colitis (1:40). On review of electronic 
health records and clinic letters, no new diagnoses other than ICP were made as a result of 
testing.
Supplementary Text 3
Autoantibody testing for anti-mitochondrial antibodies
403 (75.9%) women were tested for anti-mitochondrial antibodies, of whom five (1.2%) 
were positive; three at dilutions of 1:40; one woman tested negative on immunoblot 






























































testing, and one woman tested positive on immunoblot testing. Median liver function test 
results at time of first raised bile acid were: bilirubin 7 (IQR 7-11) µmol/L, alanine 
transaminase 47 (IQR 17-330) IU/L, and gamma-glutamyl transferase 17 (14-23) IU/L, Liver 
function tests other than bile acids were normal throughout pregnancy in one woman. In 
the four cases that were elevated during pregnancy, three normalised postpartum, and in 
one case the woman was followed up in primary care (results not available). Three women 
were referred to gastroenterology services: one was seen by a hepatologist and had liver 
and biliary magnetic resonance imaging which was normal and no further follow up was 
arranged, one was seen by a gastroenterologist and discharged, and in the final case the 
woman that tested positive on immunoblot testing was seen by a hepatologist, had a 
normal fibroscan and was discharged. In the remaining cases no referrals to specialist 
services were made and no new clinical diagnoses other than ICP were evident on electronic 
health records and clinic letters. 
Supplementary Text 4
Diagnoses in women presenting with early onset rise in bile acid concentrations
There were 23 women (4.3%) who had a peak bile acid concentration of ≥40 µmol/L at less 
than 32 weeks’ gestation, ten (43.5%) of whom had a peak bile acid concentration of ≥100 
µmol/L during pregnancy. In 12/23 cases (52.2%) ICP was the only liver diagnosis during 
pregnancy with no additional comorbidities of note. In the remaining cases pre-existing 
comorbidities, alternative explanations for the abnormal liver function tests and/ or 
additional pregnancy complications were present. In four cases (18.2%), abnormal liver 
function tests prior to pregnancy, early in pregnancy or postpartum were noted. In one case 
a woman booked with abnormal liver function but was lost to follow up after delivery, and 
in one case a woman had a history of abnormal ALT and bilirubin prior to pregnancy with 
multiple episodes of suspected biliary colic postnatally suggesting gallstone disease rather 
than ICP. Two women had persistently abnormal LFTs postpartum; one woman was 
investigated and found to be heterozygous for the ABCB4 genetic variant (Arg1046Ter) and 
homozygous for the ABCB11 Val444Ala genetic variant and in the other, the woman had not 
attended for further follow-up. Two women (9.0%) had known inflammatory bowel disease 
as well as ICP (one case of known Crohn’s disease and Primary Sclerosing Cholangitis, one 
case of known Ulcerative Colitis and Hepatitis C positive), one woman had known 






























































seropositive rheumatoid arthritis (and tested positive for anti-mitochondrial antibodies), in 
one woman cholestasis could have been triggered by an antibiotic reaction following several 
courses of antibiotics for pyelonephritis in pregnancy, one woman developed pre-eclampsia 
and HELLP syndrome, one woman was treated for tuberculosis of the spine during 
pregnancy but subsequently was diagnosed postpartum with metastatic cancer of unknown 
primary, and one woman was not diagnosed with ICP but had an episode of gallstone 
pancreatitis during pregnancy. 
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